peter attia on semaglutide Cardiovascular benefits of GLP-1 drugs independent of weight loss

This week on The Drive, I discuss the use of GLP-1 agonists for weight loss. Most notably, semaglutide (e.g., Ozempic, Wegovy) and tirzepatide (Mounjaro). I also discuss metformin as a geroprotective agent,

23.23

★★★★☆4.8 (126)

320 – AMA 64: New insights on GLP-1 agonists (Ozempic, Wegovy, Mounjaro) - efficacy, benefits, risks, and considerations in the rapidly evolving weight-loss drug landscape - The Peter Attia Drive

29.86

★★★★★4.9 (98)

How do Semaglutide and Tirzepatide work, and why are they transforming diabetes and obesity care worldwide? Join our expert-led webinar to explore the science, clinical evidence, and real-world impact of these breakthrough

22.36

★★★★★5.0 (157)

Medical FAQs Semaglutide | Potere Health MD

20.67

★★★★★4.7 (84)

Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction

28.77

★★★★★4.9 (203)

246 - AMA #45: Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent

25.15

★★★★★5.0 (176)

Semaglutide and weight management in the Arab countries: Focus on the United Arab Emirates

25.83

★★★★★4.8 (132)